[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-intraocular-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-intraocular-lymphoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100590929","phase-2-zr-mtx-for-piol-phase-ii-trial-100590929",false,"NCT06973811","ZR-MTX for PIOL Phase II Trial","A Prospective, Phase II Clinical Trial Using the Combination of Zanubrutinib, Rituximab and High-dose Intravenous Methotrexate With Intravitreal Methotrexate Injection Therapy for the Treatment of Primary Intraocular Lymphoma","ZR-MTX","Inclusion Criteria:\n\n* • Newly-diagnosed primary vitreoretinal lymphoma\n\n  * ECOG≤2\n  * creatinine clearance rate (CCR) ≥ 60ml\u002Fh, according to Cockcroft-Gault\n  * Total bilirubin # 2 upper limits of normal, alanine aminotransferase#ALT# \\\u003C 3 upper limits of normal\n  * Sign the Informed consent\n  * Women of childbearing potential must understand that the study medication could have a potential teratogenic risk. They should undergo complete contraception during the study period.\n  * Male subjects must agree to use condoms throughout study drug therapy.\n\nExclusion Criteria:\n\n* • primary central nervous system lymphoma involved eyes and brain\n\n  * systemic B cell lymphoma involved eyes\n  * Pre-existing uncontrolled active infection\n  * Clinical evidence of grade 3 or 4 heart failure as defined by the New York Heart Association criteria\n  * Pregnancy or active lactation\n  * Co-existing tumors\n  * HIV or HBV or HCV infection","ALL","18 Years","75 Years",{"count":21,"type":22},47,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is a prospective single-arm phase II study, with the purpose of evaluating the efficiency of ZR-MTX regimen (Rituximab, Zanubrutinib and methotrexate) combined with intravitreal methotrexate, then followed by minimal residual disease directed Zanubrutinib maintenance in newly-diagnosed primary intraocular lymphoma. The primary endpoint of this study is progression-free survival (PFS).",[28],"Primary Intraocular Lymphoma",[30],"primary intraocular lymphoma","RECRUITING","2026-08-04",{"date":34,"type":35},"2026-08-07","ACTUAL",{"date":37,"type":35},"2025-05-21",{"date":39,"type":22},"2029-10-30",{"name":41,"class":42},"Peking Union Medical College Hospital","OTHER"]